RhumbLine Advisers’s Applied Genetic Technologies Corporation AGTC Stock Holding History

RhumbLine Advisers’s Portfolio AGTC Stock Details AGTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-35,627	Closed	-$181K	–	3157
2021 Q1	$181K	Buy	35,627 +6,760	+23%	+$35.1K	﹤0.01%	2856
2020 Q4	$118K	Buy	28,867 +5,437	+23%	+$26.7K	﹤0.01%	2948
2020 Q3	$114K	Sell	23,430 -4,895	-17%	-$26.7K	﹤0.01%	2843
2020 Q2	$157K	Buy	+28,325	New	+$130K	﹤0.01%	2852
2017 Q2	–	Sell	-14,235	Closed	-$98K	–	2973
2017 Q1	$98K	Buy	14,235 +1,840	+15%	+$14.4K	﹤0.01%	2776
2016 Q4	$116K	Buy	12,395 +943	+8%	+$8.49K	﹤0.01%	2778
2016 Q3	$112K	Buy	11,452 +385	+3%	+$5.19K	﹤0.01%	2797
2016 Q2	$156K	Buy	+11,067	New	+$173K	﹤0.01%	2825

Other funds holding AGTC

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

RhumbLine Advisers's AGTC Position: Q2 2021 in Review

RhumbLine Advisers sold out of Applied Genetic Technologies Corporation (AGTC) in Q2 2021, closing a stake of 35,627 shares — an estimated $181K sold.

RhumbLine Advisers first reported a position in AGTC in Q2 2016 and held it in 8 quarters. The position peaked at $181K in Q1 2021. 71 funds tracked by Wall St. Rank hold AGTC as of Q2 2021.

RhumbLine Advisers reported no remaining Applied Genetic Technologies Corporation position as of Q2 2021 after selling out during the quarter.
RhumbLine Advisers sold 35,627 Applied Genetic Technologies Corporation shares in Q2 2021, an estimated $181K.
RhumbLine Advisers first reported a position in Applied Genetic Technologies Corporation in Q2 2016 and held it in 8 quarters.
RhumbLine Advisers's Applied Genetic Technologies Corporation position peaked at $181K in Q1 2021.
71 funds tracked by Wall St. Rank held Applied Genetic Technologies Corporation as of Q2 2021.

Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.